Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertensionPRESTON, Ioana R; KLINGER, James R; HOUTCHES, Jeanne et al.Respiratory medicine. 2005, Vol 99, Num 12, pp 1501-1510, issn 0954-6111, 10 p.Article

Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertensionBRESSER, P; FEDULLO, P. F; AUGER, W. R et al.The European respiratory journal. 2004, Vol 23, Num 4, pp 595-600, issn 0903-1936, 6 p.Article

Integrated pharmacokinetics and pharmacodynamics of epoprostenol in healthy subjectsNICOLAS, Laurent B; KRAUSE, Andreas; GUTIERREZ, Marcelo M et al.British journal of clinical pharmacology. 2012, Vol 74, Num 6, pp 978-989, issn 0306-5251, 12 p.Article

Identical twins with primary pulmonary hypertension: Beraprost vs epoprostenolROSENZWEIG, Erika Berman; SCHMITT, Kelly A; GAROFANO, Robert et al.Chest. 2004, Vol 125, Num 3, pp 1157-1160, issn 0012-3692, 4 p.Article

Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injuryDAHLEM, Peter; VAN AALDEREN, Wim M. C; DE NEEF, Marjorie et al.Critical care medicine. 2004, Vol 32, Num 4, pp 1055-1060, issn 0090-3493, 6 p.Article

SIDE EFFECTS OCCURRING DURING ADMINISTRATION OF EPOPROSTENOL (PROSTACYCLIN, PGI₂), IN MANPICKLES H; O'GRADY J.1982; BR. J. CLIN. PHARMACOL.; ISSN 0306-5251; GBR; DA. 1982; VOL. 14; NO 2; PP. 177-185; BIBL. 4 P.Article

Epoprostenol inhibits human platelet-leukocyte mixed conjugate and platelet microparticle formation in whole bloodTAMBURRELLI, Chiara; CRESCENT, Marilena; IZZI, Benedetta et al.Thrombosis research. 2011, Vol 128, Num 5, pp 446-451, issn 0049-3848, 6 p.Article

Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertensionTONELLI, Adriano R; ALNUAIMAT, Hassan; MUBARAK, Kamal et al.Respiratory medicine. 2010, Vol 104, Num 4, pp 481-496, issn 0954-6111, 16 p.Article

Vaso-active therapy can improve 6-min walk distance in patients with pulmonary hypertension and fibrotic interstitial lung diseaseMINAI, Omar A; SAHOO, D; CHAPMAN, J. T et al.Respiratory medicine. 2008, Vol 102, Num 7, pp 1015-1020, issn 0954-6111, 6 p.Article

Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertensionSTICHELLEHNER, Leopold; PETKOV, Ventzislav; VONBANK, Karin et al.Chest. 2003, Vol 123, Num 4, pp 1293-1295, issn 0012-3692, 3 p.Article

Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive diseaseMONTANI, D; JAIS, X; SIMONNEAU, G et al.The European respiratory journal. 2009, Vol 34, Num 6, pp 1348-1356, issn 0903-1936, 9 p.Article

Successful management of pregnancy in a patient with Eisenmenger syndrome with epoprostenolGEOHAS, Chris; MCLAUGHLIN, Vallerie V.Chest. 2003, Vol 124, Num 3, pp 1170-1173, issn 0012-3692, 4 p.Article

Successful withdrawal of long-term epoprostenol therapy for pulmonary arterial hypertensionKIM, Nick H; CHANNICK, Richard N; RUBIN, Lewis J et al.Chest. 2003, Vol 124, Num 4, pp 1612-1615, issn 0012-3692, 4 p.Article

Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertensionSULEMAN, Nizar; FROST, Adaani E.Chest. 2004, Vol 126, Num 3, pp 808-815, issn 0012-3692, 8 p.Article

Inhaled Epoprostenol During One-Lung VentilationRAGHUNATHAN, Karthik; ROY CONNELLY, Neil; ROBBINS, Larry D et al.The Annals of thoracic surgery. 2010, Vol 89, Num 3, pp 981-983, issn 0003-4975, 3 p.Article

Treatment of pulmonary arterial hypertension: The role of prostacyclin and prostaglandin analogsSAFDAR, Zeenat.Respiratory medicine. 2011, Vol 105, Num 6, pp 818-827, issn 0954-6111, 10 p.Article

Treatment of pulmonary arterial hypertension: A preliminary decision analysisHIGHLAND, Kristin B; STRANGE, Charlie; MAZUR, Joe et al.Chest. 2003, Vol 124, Num 6, pp 2087-2092, issn 0012-3692, 6 p.Article

Epoprostenol in the treatment of congestive heart failurePHILLIPS, B. B; GANDHI, A. J.American journal of health-system pharmacy. 1997, Vol 54, Num 22, pp 2613-2615, issn 1079-2082Article

CIGARETTE SMOKING DOES NOT ATTENUATE THE CARDIOVASCULAR EFFECTS OF EPOPROSTENOL (PROSTACYCLIN) IN HUMANSHASSAN S; MACDOUGALL IC; O'GRADY J et al.1982; BR. J. CLIN. PHARMACOL.; ISSN 0306-5251; GBR; DA. 1982; VOL. 14; NO 1; PP. 97-98; BIBL. 4 REF.Article

Intrapulmonary shunting in primary pulmonary hypertension: An observation in two patients treated with epoprostenol sodiumCASTRO, P. F; BOURGE, R. C; MCGIFFIN, D. C et al.Chest. 1998, Vol 114, Num 1, pp 334-336, issn 0012-3692Article

Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous Epoprostenol to intravenous TreprostinilDUNBAR IVY, D; CLAUSSEN, Lori; DORAN, Aimee et al.The American journal of cardiology. 2007, Vol 99, Num 5, pp 696-698, issn 0002-9149, 3 p.Article

Increased [¹⁸F]fluorodeoxyglucose accumulation in right ventricular free wall in patients with pulmonary hypertension and the effect of epoprostenolOIKAWA, Minako; KAGAYA, Yutaka; SHIRATO, Kunio et al.Journal of the American College of Cardiology. 2005, Vol 45, Num 11, pp 1849-1855, issn 0735-1097, 7 p.Article

Micrococcus infection in patients receiving epoprostenol by continuous infusionYAP, R. L; MERMEL, L. A.European journal of clinical microbiology & infectious diseases (Print). 2003, Vol 22, Num 11, pp 704-705, issn 0934-9723, 2 p.Article

Effects of epoprostenol on right ventricular hypertrophy and dilatation in pulmonary hypertensionROELEVELD, Roald J; VONK-NOORDEGRAAF, Anton; MARCUS, J. Tim et al.Chest. 2004, Vol 125, Num 2, pp 572-579, issn 0012-3692, 8 p.Article

Intravenous and inhaled epoprostenol for primary pulmonary hypertension during pregnancy and deliveryBILDIRICI, I; SHUMWAY, J. B.Obstetrics and gynecology (New York. 1953). 2004, Vol 103, Num 5, pp 1102-1105, issn 0029-7844, 4 p., 2Article